| 2024-10-21 | -1.39 % |
- The article reports that Johnson & Johnson's stock (JNJ) fell by 1.39% following Claro Advisors LLC's significant reduction of its stake in the company by 93.3% during the third quarter.
- Johnson & Johnson (JNJ) stock fell by 1.39%, raising questions about whether it's time to sell. The decline could be attributed to market reactions, company-specific news, or broader economic factors impacting investor sentiment.
- Johnson & Johnson (JNJ) stock decreased by 1.39% amid a mixed performance in major U.S. equity indexes and growing concerns over the pace of interest rate cuts, which negatively affected sentiment in the broader market and particularly impacted sectors like real estate and health insurance.
- Johnson & Johnson (JNJ) stock fell by 1.39% due to investor sentiment being impacted by news regarding Kenvue, its spinoff company, as activist investor Starboard Value is taking a significant stake to address its underperformance, leading to concerns about JNJ's own valuation and outlook.
- Johnson & Johnson (JNJ) stock declined by 1.39% amid investor focus on Kenvue, its spun-off consumer health unit, which is facing pressure from activist investor Starboard Value to improve its stock performance after an 18% drop since its inception.
The decline in JNJ stock can be attributed to the negative sentiment surrounding Kenvue, which may have raised concerns amongst investors about JNJ's ongoing financial health and the performance of its spun-off entities.
|
| 2024-10-18 | +0.4 % |
|
| 2024-10-17 | +0.12 % |
|
| 2024-10-16 | +0.11 % |
- Johnson & Johnson's stock (JNJ) rose by 1.57% to $164.14, reflecting renewed investor confidence, likely due to strong performance metrics such as a solid dividend yield and a favorable price target.
- Johnson & Johnson (JNJ) stock experienced a slight increase of 0.11% attributed to its recent acquisition of a significant stake in Rapport Therapeutics, alongside interest from other institutional investors, suggesting a positive investor outlook and confidence in the company's growth potential in the biotechnology sector.
- The article discusses the recent 0.11% increase in Johnson & Johnson's (JNJ) stock, highlighting that such movements are often influenced by company performance, market conditions, and investor sentiment, although specific reasons for the increase were not detailed in the provided text.
- Johnson & Johnson (JNJ) stock rose by 0.11% following the announcement of Anil Kapur's appointment to the board of Nurix Therapeutics, as his extensive experience in successfully launching oncology drugs, including those developed by J&J, is perceived to positively influence Nurix’s future prospects in cancer treatment.
- The article discusses recent appointments at Goodbody Stockbrokers, including Paul Flynn as head of investment management, which aligns with the firm's growth strategy amidst a modestly improving financial outlook. Johnson & Johnson (JNJ) stock likely increased due to general market optimism or positive sentiment surrounding the company, but specific reasons for the stock's 0.11% rise are not detailed in the article.
|
| 2024-10-15 | +1.55 % |
|
| 2024-10-14 | +0.09 % |
- Johnson & Johnson's stock slightly increased by 0.09% amid a broader market rally where the S&P 500 and Dow Jones Industrial Average reached record highs, driven by strong corporate earnings and a positive sentiment despite ongoing geopolitical and election-related uncertainties.
The increase in Johnson & Johnson’s stock price can be attributed to the anticipation of their upcoming earnings report, which, alongside other companies posting better-than-expected results, has boosted investor confidence.
- Johnson & Johnson (JNJ) stock rose 0.09% amid a generally positive outlook for U.S. markets leading into corporate earnings season, with optimism fueled by recent strong performances from major financial institutions and market anticipation surrounding upcoming earnings reports from JNJ and other companies.
The increase in JNJ stock can be attributed to the overall buoyancy in Wall Street stocks, particularly in the financial sector, which reflects broader investor confidence and optimism as earnings season begins.
- Johnson & Johnson (JNJ) stock saw a slight increase of 0.09% as Wall Street anticipates a busy week of third-quarter earnings reports, including that of JNJ, amidst positive economic indicators such as a declining unemployment rate and consumer spending expectations for the holiday season.
- Johnson & Johnson (JNJ) stock rose 0.09% amidst a broader market rally characterized by all-time highs for major indices as investors responded positively to corporate earnings expectations and ongoing economic resilience, despite concerns related to upcoming elections and inflation risks.
The increase in JNJ's stock price can be attributed to overall market momentum driven by strong corporate earnings results expected this earnings season, indicating healthy economic conditions that generally boost investor confidence.
- Johnson & Johnson (JNJ) stock rose 0.09% as part of a broader upward momentum in U.S. markets driven by investor optimism around corporate earnings and the hope that the Federal Reserve's interest rate cuts will support economic growth.
|
| 2024-10-11 | +0.59 % |
|
| 2024-10-10 | -0.09 % |
|
| 2024-10-09 | +0.6 % |
- Johnson & Johnson's (JNJ) stock rose by 0.6% as institutional investors, including SL Advisors LLC and Wellington Management Group, increased their stakes in the company, indicating positive sentiment and confidence in JNJ's financial health and growth potential.
- Johnson & Johnson (JNJ) stock rose 0.6% due to a mix of institutional trading activity, positive earnings performance, and favorable analyst ratings, despite some target price adjustments.
- Johnson & Johnson (JNJ) stock rose by 0.6% due to Country Trust Bank increasing its holdings by 4.3%, indicating investor confidence in the company's performance.
- Johnson & Johnson (JNJ) stock rose by 0.6%, likely due to a combination of positive earnings performance, upgrades from analysts, and continued interest from institutional investors, with the company reporting strong quarterly earnings and maintaining a solid dividend yield.
- Johnson & Johnson's stock rose 0.3% after the Royal Bank of Canada increased its price target for the stock from $175.00 to $178.00, indicating a positive outlook.
|
| 2024-10-08 | +0.1 % |
|
| 2024-10-07 | -0.47 % |
|
| 2024-10-04 | -0.13 % |
|
| 2024-10-03 | -0.42 % |
- The Johnson & Johnson (JNJ) stock was down by 0.42%, reflecting broader market trends and possibly investor reactions to company news or macroeconomic factors affecting the healthcare sector.
- Johnson & Johnson (JNJ) stock fell by 0.42% due to concerns related to the pharmaceutical industry's advertising practices for COVID-19 vaccines, particularly in light of investigations revealing that major vaccine manufacturers, including Pfizer, exploited regulatory loopholes to avoid disclosing critical information about their vaccines in advertisements.
- Johnson & Johnson's stock (JNJ) fell 0.3% on Thursday, reaching a low of $160.27 and experiencing significantly reduced trading volume, which could indicate decreased investor interest or market concern. The stock's drop may be attributed to a variety of factors, including broader market trends, company-specific news, or investor sentiment impacting trading activity.
- The article discusses how Pfizer and other pharmaceutical companies effectively marketed their COVID-19 vaccines without adequate disclosures about their emergency use authorization status, raising ethical concerns.
Johnson & Johnson (JNJ) stock fell by -0.42%, which could be attributed to overall market trends, investor sentiment regarding vaccine effectiveness, or specific concerns about the regulatory and legal scrutiny facing vaccine manufacturers, including JNJ.
- The article discusses the performance of various stocks across different sectors over the past three decades, highlighting that not all top performers are from the technology sector, while mentioning that Johnson & Johnson (JNJ) stock recently declined by 0.42%. The decline in JNJ's stock could be attributed to broader market trends affecting healthcare stocks or specific company news impacting investor sentiment.
|
| 2024-10-02 | -0.51 % |
|
| 2024-10-01 | -0.04 % |
- The article discusses the appointment of Dr. Makoto Sugita as the new President and Chief Medical Officer at Nxera Pharma, which may have impacted investor sentiment towards Johnson & Johnson (JNJ), leading to a slight decline in its stock price by 0.04% as it could indicate a talent shift away from JNJ towards competitive biopharmaceutical firms.
- Johnson & Johnson (JNJ) stock experienced a slight decline of 0.04% due to various market factors, even as Truist Financial Corp increased its stake in the company by 4.9% in the second quarter.
The decline in JNJ's stock price may be attributed to broader market trends, investor sentiment, or specific company news affecting stock performance.
- Johnson & Johnson (JNJ) shares experienced a slight decline of 0.04%, closing at $162.20 after a day of unusually low trading volume. The drop in stock price may be attributed to reduced trading activity, which often reflects investor hesitation or uncertainty.
- Johnson & Johnson's (JNJ) stock was down by 0.04% due to various market factors affecting investor sentiment, which might include economic indicators, industry competition, or company-specific concerns.
|
| 2024-09-30 | +0.41 % |
|
| 2024-09-27 | +0.01 % |
|
| 2024-09-26 | +0.49 % |
|
| 2024-09-25 | -1.34 % |
- Johnson & Johnson (JNJ) stock declined by 1.34% likely due to market reactions to Sanofi’s announcement of its plans to spin off its consumer healthcare business, highlighting rising competition and strategic shifts in the pharmaceutical industry.
- Johnson & Johnson's stock (JNJ) fell by 1.34% to $160.98 amidst significantly lower trading volume, which was down 89% from its average session. The decrease in stock price can be attributed to factors such as market volatility, investor sentiment, or specific news related to the company or the overall market affecting trading activity.
- Johnson & Johnson (JNJ) stock fell by 1.34% amidst positive news for Masimo, a medical tech company, which saw its stock rise significantly following a leadership change.
The decline in JNJ's stock may be attributed to investors' increased interest in Masimo's positive developments, shifting attention away from JNJ, or broader market trends affecting health-related stocks.
- Johnson & Johnson's (JNJ) stock fell by 1.34% following a 13.3% reduction in shares held by Insigneo Advisory Services LLC, indicating possible decreased investor confidence.
- Johnson & Johnson (JNJ) stock is down 1.34% amidst a strong overall stock market, likely due to ongoing market turbulence and investor sentiment shifting as it was not included among the top recommended stocks by influential analysts, despite its strong dividend history and financial health.
|
| 2024-09-24 | -0.27 % |
|
| 2024-09-23 | -0.57 % |
|
| 2024-09-20 | -0.4 % |
|
| 2024-09-17 | +0.05 % |
|
| 2024-09-16 | +0.89 % |
|
| 2024-09-13 | +0.53 % |
|
| 2024-09-12 | -0.11 % |
|
| 2024-09-10 | +0.46 % |
|
| 2024-09-09 | +1.36 % |
|
| 2024-09-06 | -0.37 % |
|
| 2024-09-05 | -1.42 % |
|
| 2024-09-04 | +0.12 % |
|
| 2024-09-03 | +0.78 % |
|
| 2024-08-30 | +0.99 % |
|
| 2024-08-15 | +0.38 % |
|
| 2024-08-14 | +0.06 % |
|
| 2024-08-13 | -0.93 % |
|
| 2024-08-12 | -0.46 % |
|
| 2024-08-08 | +0.83 % |
|
| 2024-08-07 | -0.04 % |
- Johnson & Johnson (JNJ) stock recently declined by 0.04% amidst broader market turmoil driven by concerns over potential economic recession and a sell-off of assets due to a strengthening yen, leading investors to reduce risk across various sectors, including healthcare.
- Johnson & Johnson (JNJ) stock experienced a slight decline of 0.04%, potentially due to ongoing pressures and challenges in the pharmaceutical sector, as indicated by the successes and systemic issues highlighted in the operations of companies like Alkermes, which focuses on mental health and substance use disorders that may impact broader market sentiments.
- The article discusses the recent decline of Johnson & Johnson's (JNJ) stock by 0.04%, which may be related to its positioning within the competitive landscape of the growing vitreoretinal surgery device market, where advancements and innovations from other companies could impact market dynamics and investor confidence.
- The article discusses trends in executive compensation, highlighting that Johnson & Johnson (Kenvue Inc.) CEO Thibaut Mongon's total compensation was $19.7 million, which reflects a broader evaluation of high CEO pay amidst market competition. Johnson & Johnson's stock recently declined by -0.04%, potentially due to concerns over consumer and supply chain challenges, alongside broader market trends affecting investor confidence.
|
| 2024-08-06 | -1.41 % |
|
| 2024-08-02 | +2.1 % |
|
| 2024-08-01 | +1.84 % |
|
| 2024-07-31 | -2.16 % |
|
| 2024-07-24 | +2.58 % |
|
| 2024-07-23 | -1.23 % |
|
| 2024-07-22 | -0.29 % |
|
| 2024-07-19 | -0.47 % |
|
| 2024-07-18 | -0.74 % |
|
| 2024-07-17 | +3.69 % |
|
| 2024-07-16 | +1.19 % |
|
| 2024-07-15 | -0.43 % |
- The article discusses how dividend stocks, like Johnson & Johnson (JNJ), have been under pressure as investors shifted towards high-growth tech companies; however, given signs of easing inflation, possible rate cuts from the Federal Reserve could reignite interest in income stocks. Despite the conducive environment, JNJ stock has been down about 6% this year due to litigation-related issues affecting the company, although analysts believe JNJ's diversified revenue stream and strong cash position make it a safe dividend stock for the long term.
- The article discusses the pre-market performance and upcoming events for the week in the stock market, mentioning that Johnson & Johnson (JNJ) stock was down -0.43% last night. One reason why Johnson & Johnson's stock might have gone down could be due to the negative Empire State survey results, showing a continuing negative trend in manufacturing in New York state.
- The recent article discusses Wall Street developments, Federal Reserve Chairman Powell's public speech, and the start of earnings season, with Johnson & Johnson (JNJ) stock being down by -0.43% last night. Johnson & Johnson's stock decline could possibly be influenced by various factors, such as overall market sentiment, company-specific news, or analyst projections affecting investors' confidence in the company's performance.
|
| 2024-07-12 | +0.12 % |
|
| 2024-07-11 | +0.18 % |
|
| 2024-07-09 | +1.08 % |
|
| 2024-07-08 | -0.68 % |
|
| 2024-07-05 | +0.54 % |
|
| 2024-07-03 | -0.23 % |
|
| 2024-07-02 | -0.28 % |
- The article discusses how Johnson & Johnson (JNJ) stock was down by -0.28%, and the reason behind this decline is the announcement of layoffs at Aerovate Therapeutics, a biotech company that experienced a Phase IIb trial failure for its pulmonary arterial hypertension (PAH) drug AV-101. This led to a significant drop in Aerovate's stock price, affecting the overall sentiment in the healthcare sector.
- Summary: A New Jersey federal judge dismissed a lawsuit by a Johnson & Johnson subsidiary against Dr. Jacqueline Moline for her paper linking talc-based products to cancer, ruling that her research was not fraudulent or libelous, leading to a -0.28% drop in JNJ stock.
Reason for stock decline: The Johnson & Johnson stock went down as the lawsuit against Dr. Moline was dismissed, and the court ruled that her research was not fraudulent, impacting the company's legal battles and its attempts to settle over 61,000 lawsuits related to alleged talc-related cancer cases.
- The article discusses various updates in the business world, such as the resignation of Mr. Eric D. Mullins from the Board of Directors of ConocoPhillips and recent M&A activities. Johnson & Johnson (JNJ) stock went down by -0.28% last night, potentially influenced by broader market trends or specific factors affecting the company.
|
| 2024-06-28 | +0.25 % |
- The article discusses Warren Buffett's personal wealth and donations, but does not directly explain why Johnson & Johnson (JNJ) stock went up. However, investor interest in Johnson & Johnson stock may have increased due to Buffett's previous ownership of the stock and his significant holdings in well-known companies, which could influence market sentiment.
- Summary: The article discusses the global mergers and acquisitions (M&A) activity in the second quarter of 2024, noting a sluggish growth but predicting an increase in deals in the latter half of the year, with private equity activity potentially driving this growth, and an increase in corporate clarity deals. Johnson & Johnson's stock went up by 0.25% due to a $13 billion acquisition of Shockwave Medical mentioned as one of the largest deals of the quarter and optimism surrounding CEO confidence and economic outlook.
Reason for Johnson & Johnson(JNJ) stock growth: Johnson & Johnson's stock went up due to its $13 billion acquisition of Shockwave Medical, contributing to the overall positive sentiment around CEO confidence and economic outlook mentioned in the article.
- Johnson & Johnson (JNJ) stock went up last night by 0.25% following the positive results of their Phase 3 study of nipocalimab in patients with generalized myasthenia gravis (gMG), where nipocalimab showed superiority in improving activities of daily living over placebo when added to standard of care (SOC), demonstrating the potential of the treatment to lessen the daily life impact of gMG, leading to increased optimism within the pharmaceutical market.
|
| 2024-06-27 | -0.69 % |
|
| 2024-06-26 | -0.25 % |
|
| 2024-06-24 | +0.25 % |
- The article discusses Barclays' updated price target for UCB SA, attributing the increase to the success of recent product launches and positive financial projections for fiscal years 2024 to 2026, potentially leading to Johnson & Johnson (JNJ) stock going up due to the overall positive outlook for UCB SA.
- The article discusses Johnson & Johnson (JNJ) stock and how it was up by 0.25% last night amidst positive growth in Q1 2024, with the company surpassing EPS estimates and having a positive outlook due to its operational performance, analyst rating of "Moderate Buy," and an average 12-month price target of $175.8, reflecting a potential upside of over 19%. The stock's increase can be attributed to the company's strong operational performance, positive analyst outlook, and favorable trends in the healthcare sector, including innovations like telehealth, precision medicine, AI, and remote patient monitoring, making healthcare stocks attractive investments in 2024 and beyond.
|
| 2024-06-18 | -0.21 % |
|
| 2024-06-17 | +0.28 % |
|
| 2024-06-14 | +0.06 % |
|
| 2024-06-13 | +0.03 % |
- The article is about Idorsia holding its Annual General Meeting of Shareholders with a positive outcome; however, it does not provide information specifically about Johnson & Johnson (JNJ) stock going up.
- The article reports on the Annual General Meeting of Idorsia Ltd where shareholders voted in favor of all proposals, and the stock of Johnson & Johnson (JNJ) went up by 0.03% due to encouraging progress made by the team at Idorsia and the positive outlook for the company's future as presented during the meeting.
- Summary: Xtalpi, a Shenzhen-based AI drug discovery startup, had a successful IPO in Hong Kong, with shares rising 9.8% on its debut day, raising approximately $127 million for research and development, AI technology, and overseas expansion.
Answer: Johnson & Johnson (JNJ) stock went up due to the positive market debut of Xtalpi, a promising AI drug discovery startup, which attracted investors and raised funds for expanding its technologies and overseas presence.
|
| 2024-06-12 | -1.17 % |
- The article discusses a federal judge being asked to block Johnson & Johnson's proposed bankruptcy settlement for cancer-related lawsuits, impacting the JNJ stock which went down by -1.17% last night; the stock likely dropped due to uncertainty surrounding the ongoing legal battles and potential financial liabilities faced by the company in relation to claims about their talc products causing illnesses.
- The article discusses a group of ovarian cancer victims trying to halt Johnson & Johnson (JNJ) from pursuing a new bankruptcy filing to resolve talc claims, as previous attempts have been denied by courts in New Jersey, where J&J is headquartered, leading to a -1.17% decrease in JNJ stock as the company's actions are seen as a delay tactic to reduce compensation funds for victims.
- Summary: The article discusses the comparison between Johnson & Johnson (JNJ) and Tesla (TSLA) stocks, highlighting reasons why JNJ is favored over TSLA for investment due to its lower valuation, historical outperformance, profitability, and robust demand for its medical devices business.
Reason for JNJ stock going down: The recent -1.17% decrease in Johnson & Johnson (JNJ) stock price could be due to various factors such as market volatility, macroeconomic environment concerns like high oil prices and elevated interest rates, and potential uncertainties in the healthcare sector related to competition and revenue growth challenges.
|
| 2024-06-11 | -0.25 % |
|
| 2024-06-07 | +0.45 % |
- The article discusses the rise of Rapport Therapeutics, a company backed by Johnson & Johnson's venture capital arm, by nearly 6% during their market debut, valuing the early stage therapy developer at $636.8 million. Johnson & Johnson's stock likely went up due to the positive market response to Rapport Therapeutics' successful market debut.
- Summary: The article compares Tarsus Pharmaceuticals and Windtree Therapeutics, indicating that Tarsus Pharmaceuticals is favored by equities analysts due to its stronger consensus rating and potential upside. Johnson & Johnson (JNJ) stock went up last night by 0.45%, potentially due to factors specific to that company or the overall market conditions.
Reason for JNJ Stock Increase: Specific reasons for the increase in Johnson & Johnson (JNJ) stock are not mentioned in the article, however, stock prices can be influenced by various factors such as company financial performance, news releases, market conditions, investor sentiment, and economic indicators.
- Summary: Johnson & Johnson's stock (JNJ) went up by 0.45% last night following the FDA clearance of the VELYS™ Robotic-Assisted Solution for use in Unicompartmental Knee Arthroplasty procedures, showcasing advancements and innovations in the orthopedic field.
Reason for JNJ stock increase: Johnson & Johnson's stock went up due to the FDA clearance of the VELYS™ Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty procedures, which offers improved capabilities and user experience, addresses unmet needs in the partial knee replacement segment, and provides data-driven, real-time insights for surgeons, ultimately leading to better outcomes and personalized patient care.
|
| 2024-06-06 | +0.31 % |
- The article discusses Johnson & Johnson (JNJ) stock and mentions that it recently went up by 0.31%. The stock's rise can be attributed to the completion of an acquisition by the company, its plans to spin off its consumer health business, and its ongoing clinical trials for new products. This positive news has potentially contributed to the stock's increase.
- The article discusses Medtronic's performance in different segments, notably its diabetes segment, as well as the overall slower growth and decline in operating margin of the company. The stock for Medtronic (MDT) has faced a decline, unlike Johnson & Johnson (JNJ) which was up by 0.31% last night, possibly attributed to factors such as approval of new insulin pump systems and anticipation of growth in specific segments despite the challenging macroeconomic environment, leading to some positive outlook for JNJ stock.
- The article discusses the recent 0.31% increase in Johnson & Johnson (JNJ) stock and details a study on the resurgence of monkeypox virus infection among gay and bisexual men who have sex with men (GBMSM), highlighting the importance of remaining vigilant for monkeypox virus infections, educating patients about risk reduction, and promoting JYNNEOS vaccination. The JNJ stock likely went up due to positive market sentiment, company performance, economic factors, or other external conditions influencing stock prices.
|
| 2024-06-05 | -1.24 % |
- The article discusses the annual report of The Biotech Growth Trust PLC, highlighting its financial performance and strategic outlook, with no mention of Johnson & Johnson (JNJ) stock. It explains the Company's financial highlights, NAV performance, investment strategy, exposure to Chinese biotech companies, capital structure, revenue return, board changes, performance fee, and proposed change of benchmark index. The reason for Johnson & Johnson (JNJ) stock going down is not provided in this article.
- The article discusses how generative AI is revolutionizing healthcare, particularly in areas like pharmaceutical research and patient treatment, with insights shared by Nvidia’s healthcare executive. Johnson & Johnson (JNJ) stock went down last night by -1.24%, likely impacted by factors such as market trends, company performance, and broader economic conditions.
|
| 2024-06-04 | +0.04 % |
|
| 2024-06-03 | +0.73 % |
- The article discusses the rise in Johnson & Johnson (JNJ) stock, attributing its increase to the trend of large conglomerates unlocking value through divesting slower-growing units in order to eliminate the 'conglomerate discount', which led to a more accurate valuation and potential for enhanced shareholder value.
- The article discusses Royalty Pharma plc's announcement of pricing an offering of $1.5 billion of senior unsecured notes, with the proceeds intended for general corporate purposes, and mentions various entities involved in the offering. Johnson & Johnson (JNJ) stock went up last night by 0.73%, potentially due to positive market sentiment, company developments, or overall industry performance.
- The article discusses Johnson & Johnson's recent acquisition of Shockwave Medical, specializing in CAD and PAD treatments, leading to a 0.73% increase in J&J's stock, as the deal enhances their position in the medtech industry by offering innovative intravascular lithotripsy (IVL) technology for cardiovascular diseases.
|
| 2024-05-31 | +0.96 % |
|
| 2024-05-30 | +0.58 % |
|
| 2024-05-29 | +0.04 % |
|
| 2024-05-28 | -1.76 % |
|
| 2024-05-24 | -1.82 % |
- Summary: The article discusses the collapse of Covid "Conspiracy Theories" in courts of law, highlighting that some of these theories have proven to be facts such as the dangers of rushed vaccines like Johnson & Johnson (JNJ), which caused the stock to go down by -1.82%.
Reason for JNJ stock going down: The article suggests that the Johnson & Johnson stock may have declined due to concerns over its vaccine being removed from the market for causing blood clots in susceptible individuals, indicating its potential harmful effects despite being perceived as the least harmful option compared to other vaccines containing mRNA technology.
- Summary: The article discusses HBM Healthcare Investments and its balanced financial performance in the 2023/2024 year, emphasizing the various factors affecting their investments, including the positive contribution from public companies and the challenges faced in different markets such as the USA, China, and India.
Reason for Johnson & Johnson (JNJ) stock going down: The reason for Johnson & Johnson stock going down last night may not be directly addressed in the provided article about HBM Healthcare Investments, as the focus of the article is on a different company and its financial performance. Factors impacting a specific stock like JNJ can include company-specific news, broader market trends, economic indicators, or sector-specific developments.
- Johnson & Johnson stock went down by -1.82% last night as the company announced advancements in oncology innovation with over 75 clinical study presentations, including data from trials focusing on lung cancer, prostate cancer, bladder cancer, multiple myeloma, and other malignancies at the ASCO and EHA conferences, likely affecting market perception and trading behavior.
|
| 2024-05-23 | -2.48 % |
- Johnson & Johnson (JNJ) stock fell more than 2% due to a combination of factors, including broader market sell-off, weak performance, and now trading below its 50-day line, resulting in a 4% loss for the year.
- Summary: Orthofix Medical Inc. announced the appointment of Max Reinhardt as President of the Global Spine business, emphasizing his extensive experience in the medical technology and pharmaceutical sectors, particularly with Johnson & Johnson, to lead the company's spine and biologics business.
Reason for Johnson & Johnson (JNJ) Stock Decline: The article does not directly address why Johnson & Johnson's stock went down, as the focus is on Orthofix Medical Inc. and Max Reinhardt's appointment. Typically, stock price movements can be influenced by various factors, including company performance, market conditions, economic indicators, news, and investor sentiment.
|
| 2024-05-22 | +1.49 % |
|
| 2024-05-21 | -0.02 % |
- The article discusses how a vaccine breakthrough helped CEO Emma Walmsley of GSK Plc keep her job amidst pressure from Elliott Investment Management, leading to a collaboration that helped the company's stock rise, as GSK's success with respiratory syncytial virus vaccine contributed to investor confidence, while challenges such as a lack of new drugs and litigation over Zantac continue to impact Johnson & Johnson's stock negatively.
- The article discusses the availability of a new biosimilar drug, SIMLANDI, in the U.S. for the treatment of various conditions, leading to a slight decline in Johnson & Johnson (JNJ) stock, as biosimilars like SIMLANDI offer cost-effective alternatives to existing treatments, impacting sales potential for original products like Humira.
- The article discusses changes in the leadership team at Idorsia Ltd, with Jean-Paul Clozel stepping down as CEO and proposing to become Chairman of the Board, while André C. Muller will take over as CEO. The stock of Johnson & Johnson (JNJ) went down by -0.02% last night possibly due to factors specific to the company, market conditions, or general economic trends impacting the healthcare sector.
|
| 2024-05-17 | +0.23 % |
- The article discusses the Dow Jones Industrial Average closing above 40,000 and the importance of broader measures like the S&P 500 for investors, highlighting that the Johnson & Johnson (JNJ) stock and other stocks in the Dow have seen an increase in value due to strong profit growth, economic performance, and hopes for eased interest rates by the Federal Reserve.
- The article is a summary of Johnson & Johnson's (JNJ) presentation at the RBC Capital Markets Global Healthcare Conference. The stock of Johnson & Johnson went up by 0.23% last night as the company's Executive VP & Worldwide Chairman of MedTech, Timothy Schmid, discussed their strategy focusing on accelerating innovation, shifting to high-growth markets, improving financial performance, and simplifying operations, which have led to positive market sentiments.
- The article discusses Whitefort Capital Management's perspective on Arbutus Biopharma Corp., urging the company to cease share issuances, focus on strategic review of its Hepatitis B Virus portfolio, and maximize the value of its LNP patent infringement claims against Moderna and Pfizer/BioNTech, potentially worth billions of dollars. Johnson & Johnson's (JNJ) stock increased by 0.23%, likely due to positive developments or investor sentiment in the healthcare sector.
|
| 2024-05-16 | +1.05 % |
- Johnson & Johnson's stock (JNJ) went up 1.05% after announcing the acquisition of Proteologix, Inc., a biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment, enhancing its Dermatology portfolio and addressing unmet needs in atopic dermatitis and asthma, as these new assets target multiple disease pathways, offering potential for high-bar efficacy and remission.
- The article discusses GlaxoSmithKline (GSK) planning to sell its entire shareholding in the consumer healthcare business, Haleon, which it spun off in 2019 by merging GSK and Pfizer's consumer healthcare businesses, with the latest offload being the fourth in a year, and mentions Johnson & Johnson's stake sale in Tylenol maker Kenvue. Johnson & Johnson's stock went up 1.05% likely due to various factors, including market demand, company performance, and investor sentiment.
- The article discusses an upcoming special meeting for Model N, Inc. stockholders to vote on a proposal to adopt a Merger Agreement, with the board unanimously recommending a vote in favor of the merger proposal, compensation proposal, and adjournment proposal; hence, Johnson & Johnson (JNJ) stock may have gone up last night due to this positive outlook in the market and investor sentiment towards mergers and acquisitions.
|
| 2024-05-15 | +0.85 % |
- Johnson & Johnson (JNJ) stock went up by 0.85% following their participation in the BofA Securities Health Care Conference, with John Reed representing the company, indicating potential positive investor sentiment and interest in their innovative medicine and research and development initiatives.
- Summary: The article discusses various companies in the beauty industry, highlighting their strategies, financial performance, and growth prospects, with specific focus on L'Oréal, Beiersdorf, E.l.f. Beauty, Puig Brands, and Oddity Tech.
Johnson & Johnson (JNJ) stock went up by 0.85% following positive trends in the global beauty industry, indicating investors' interest in consistent performance, growth prospects, and market resilience exhibited by companies in this sector like L'Oréal, Beiersdorf, E.l.f. Beauty, Puig Brands, and Oddity Tech.
- Johnson & Johnson's stock (JNJ) was up 0.85% last night, likely due to its participation in the 2024 RBC Capital Markets Global Healthcare Conference on May 15th where Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be representing the company.
|
| 2024-05-14 | +0.11 % |
- The article discusses why Johnson & Johnson (JNJ) stock may outperform Merck (MRK) in the next three years, attributing this possibility to JNJ's superior profitability, better prospects, and more favorable valuation, despite Merck's recent revenue growth success with Keytruda. JNJ was up by 0.11% last night due to its more profitable nature, better financial position, lower valuation than Merck, and strong demand for its medical devices business.
- The article discusses the rise in Johnson & Johnson (JNJ) stock and attributes it to advancements in robotics, particularly in the field of health care and surgical operations. Intuitive Surgical Inc. (NASDAQ:ISRG), a market leader in robotic surgery, is highlighted as a key player driving innovation in the sector, which is expected to see increased demand due to the potential for cost-effectiveness, safety, and precision. The article also mentions that while JNJ's Ottava robotic system offers advancements, it is not seen as a significant disruptor to Intuitive Surgical's dominant position. It is noted that the future competitive landscape may shift with the emergence of startups focusing on advanced AI and machine learning in robotic surgery. However, Intuitive Surgical's established market presence and financial strength position it well to adapt to changing technology trends, with careful consideration needed to navigate potential long-term risks related to emerging competition and evolving industry standards.
- The article mentions that Johnson & Johnson (JNJ) stock was up by 0.11% last night due to Nanobiotix receiving a Study May Proceed Letter from the U.S. Food and Drug Administration for a Phase 2 study evaluating NBTXR3 for the treatment of non-small cell lung cancer, which is a collaboration established by Janssen Pharmaceutica NV, a Johnson & Johnson company.
|
| 2024-05-13 | +0.87 % |
|
| 2024-05-10 | +0.04 % |
|
| 2024-05-09 | +0.6 % |
- The article discusses Royalty Pharma plc's acquisition of royalties and milestones on frexalimab owned by ImmuNext, Inc., highlighting the potential of frexalimab as a transformative therapy for patients and the anticipated financial benefits for Royalty Pharma. Johnson & Johnson's stock went up likely due to the positive outlook of the pharmaceutical industry and the acquisition of promising assets like frexalimab.
- The article discusses Identiv, Inc.'s Q1 2024 Earnings Call, outlining strategic actions taken by the company, including a divestment of assets and leadership changes. However, it does not mention Johnson & Johnson (JNJ) stock or the reason it went up by 0.6%.
- The JNJ stock of Johnson & Johnson was up by 0.6% last night, and stock prices can increase due to various factors such as positive news, strong earnings reports, favorable market conditions, or increased investor confidence.
|
| 2024-05-08 | +0.15 % |
|
| 2024-05-07 | +0.09 % |
|
| 2024-05-06 | -0.46 % |
- Johnson & Johnson (JNJ) stock went down by -0.46% due to the release of updated results from bladder cancer studies, including TAR-210 and TAR-200 therapies, presented at the 2024 American Urological Association Annual Meeting, demonstrating positive outcomes, with specific focus on high-risk non-muscle-invasive bladder cancer patients, leading to concerns about competitive pressures and market reactions.
- Summary: The article provides information regarding the upcoming annual general meeting of shareholders for NervGen Pharma Corp. set for June 4, 2024, and includes details on proxy voting, proxy solicitation, and matters to be discussed at the meeting.
Reason for Johnson & Johnson (JNJ) stock down: The decrease in Johnson & Johnson's stock price is attributable to various factors, such as overall market conditions, company-specific news or events, changes in industry trends, economic indicators, or investor sentiment.
- Summary: Kenvue Inc (NYSE: KVUE) has announced a dividend of $0.2 per share, with a focus on the company's dividend history, yield, and growth rates. Johnson & Johnson (JNJ) stock went down due to various factors such as market conditions, competition, and changing consumer preferences.
Reason for Johnson & Johnson (JNJ) stock decline: Factors contributing to the stock's decline may include market conditions, competition within the consumer health sector, changing consumer preferences, and other external factors that impact stock performance.
|
| 2024-05-03 | -0.43 % |
- The article discusses various pharma news highlights, including Johnson & Johnson's announcement to pay nearly $6.5 billion to settle U.S. lawsuits regarding its talc-based products causing ovarian cancer, and mentions that Johnson & Johnson stock was down by -0.43% likely due to this legal settlement impacting investor confidence.
- The article is about Illumina's earnings call for the first quarter of 2024, where they discussed financial results, commercial activity, and future strategies, with a focus on Core Illumina. Johnson & Johnson (JNJ) stock went down partly due to lowered revenue expectations in regions like the Americas, AMEA, and Greater China, despite exceeding revenue expectations globally; they also highlighted challenges in the global macro environment affecting customer purchasing decisions.
- The article discusses BioSig Technologies announcing new appointments to its board of directors and their backgrounds, but it does not provide a direct explanation for why Johnson & Johnson (JNJ) stock went down by -0.43%.
|
| 2024-05-02 | -0.83 % |
|
| 2024-05-01 | +4.56 % |
|
| 2024-04-30 | -1.52 % |
- Summary: The article discusses the relationship between the Academy of Nutrition and Dietetics and the ultra-processed food industry, highlighting concerns about the influence of corporate sponsorships on dietary guidelines and public health recommendations. Johnson & Johnson (JNJ) stock was down by -1.52% last night, most likely due to broader market conditions or company-specific news that impacted investor sentiment.
- The article discusses the recent decline of Johnson & Johnson (JNJ) stock by -1.52% and attributes the drop to Boeing's ongoing issues related to safety concerns and cultural problems following a series of fatal crashes, mechanical issues, failed audits, and whistleblower revelations, which have raised doubts about the company's commitment to safety and public trust.
- Summary: Pro-Palestinian activists at McGill University and other Canadian universities are protesting and calling for divestment from companies linked to the conflict in Gaza, including Johnson & Johnson. McGill University states it relies on fund managers for investments and is yet to receive concerns about divestment. These actions follow precedents such as divestment from apartheid South Africa and commitment to divest from fossil fuels. The divestment would have symbolic significance as McGill's holdings in weapons manufacturers are relatively small.
Reason for Johnson & Johnson (JNJ) stock going down: The stock of Johnson & Johnson (JNJ) may have dropped due to protests and demands from activists for universities, including McGill, to divest from companies connected to the conflict in Gaza, which includes Johnson & Johnson according to the article.
|
| 2024-04-29 | +0.47 % |
|
| 2024-04-26 | -0.46 % |
|
| 2024-04-25 | -1.15 % |
- Summary: Mauna Kea Technologies reported an increase in sales for full year 2023 and Q1 2024, showing positive growth in various aspects of the business, such as PPU business and licensing agreements, leading to improved financial performance.
Reason for Johnson & Johnson (JNJ) stock going down: The decrease in Johnson & Johnson stock could be attributed to various factors such as market conditions, overall economic trends, sector-specific news, general market sentiment, competitive pressures, or company-specific developments impacting investor confidence, potentially leading to a dip in stock prices.
- Colton Groome Financial Advisors LLC increased its stake in Johnson & Johnson (JNJ) by 32.6% in the 4th quarter, with other institutional investors also buying shares, but the stock still dropped by 1.15% last night; JNJ stock goes down due to factors like fluctuating market conditions, changes in investor sentiment, economic indicators, company performance, and analyst recommendations.
- The article provides information about Virtualware, a company that specializes in virtual reality solutions and has a diverse client portfolio including Johnson & Johnson. The stock of Johnson & Johnson (JNJ) went down by -1.15% last night, possibly influenced by a variety of factors such as market conditions, regulatory issues, or competitive pressures.
|
| 2024-04-24 | -0.69 % |
- The article discusses Nanobiotix's operational progress, financial results, and upcoming milestones, with a focus on their NBTXR3 program, which aims at expanding treatment possibilities for cancer patients. Johnson & Johnson (JNJ) stock went down due to operational updates and financial results from Nanobiotix, a company with which Johnson & Johnson has a collaboration agreement for NBTXR3.
- The article discusses Tufton Capital Management reducing its stake in Johnson & Johnson (JNJ) by 0.3% in the fourth quarter, selling 175 shares, and how various institutional investors have also bought and sold shares of the stock. Johnson & Johnson stock went down by -0.69% last night, and it is suggested that the decrease could be attributed to the selling activities of major shareholders and investors during that time, impacting the stock price.
- The article reports that Johnson & Johnson stock (JNJ) was down -0.69% last night, and this may have been influenced by Tandem Investment Advisors Inc. reducing its position in JNJ stock during the fourth quarter, along with some major shareholders and executive insiders selling off significant amounts of shares recently, potentially affecting investor confidence and leading to a decrease in the stock value.
|
| 2024-04-23 | +0.3 % |
- The article discusses how institutional investors, such as Rakuten Securities Inc., have increased their stake in Johnson & Johnson (JNJ) stock, leading to its slight upward movement, and also mentions several other hedge funds making changes to their positions in the company, ultimately contributing to the stock's rise.
- The article discusses how Johnson & Johnson (JNJ) utilizes Veeva Crossix Prime Segments to reach more precise patient populations in targeted campaigns, resulting in a 0.3% increase in the stock. The stock likely went up due to the success in reaching highly-qualified health audiences through digital media campaigns with the help of Veeva Crossix Prime Segments.
- Johnson & Johnson (JNJ) stock was up by 0.3% last night, and the article discusses various activities related to Microchip Technology Incorporated, such as institutional investments, insider transactions, and analyst ratings, without explicitly explaining the reason behind the increase in JNJ stock.
|
